CAR-NK cells deliver quick, antigen-independent killing through ADCC and innate receptors (NKG2D, DNAM-1), and may reduce CAR-T exhaustion and cytokine-release toxicity by rapidly decreasing tumour size. The gene discussed is KLRK1; the disease is neoplasm.